Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Andringa

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Hippocampus|January 1, 1997
Exposure to chronic psychosocial stress and corticosterone in the rat: effects on spatial discrimination learning and hippocampal protein kinase Cgamma immunoreactivityH J Krugers, B R Douma, G Andringa, et al.
Behavioural Pharmacology|April 26, 2000
The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297G Andringa, R J Vermeulen, B Drukarch, et al.
The European Journal of Neuroscience|September 6, 2000
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigraG Andringa, R V van Oosten, W Unger, et al.
Neuropathology and Applied Neurobiology|April 8, 2006
Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrainG Andringa, J G J M Bol, X Wang, et al.
Synapse (New York, N.Y.)|November 5, 1997
[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeysJ Booij, G Andringa, L J Rijks, et al.
Neurobiology of Aging|August 18, 2004
Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigraF L van Muiswinkel, R A I de Vos, J G J M Bol, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Hippocampus|January 1, 1997
Exposure to chronic psychosocial stress and corticosterone in the rat: effects on spatial discrimination learning and hippocampal protein kinase Cgamma immunoreactivityH J Krugers, B R Douma, G Andringa, et al.
Behavioural Pharmacology|April 26, 2000
The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297G Andringa, R J Vermeulen, B Drukarch, et al.
The European Journal of Neuroscience|September 6, 2000
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigraG Andringa, R V van Oosten, W Unger, et al.
Neuropathology and Applied Neurobiology|April 8, 2006
Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrainG Andringa, J G J M Bol, X Wang, et al.
Synapse (New York, N.Y.)|November 5, 1997
[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeysJ Booij, G Andringa, L J Rijks, et al.
Neurobiology of Aging|August 18, 2004
Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigraF L van Muiswinkel, R A I de Vos, J G J M Bol, et al.
Pageof 2